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Abstract
Background: Galectin-3 (Gal3) plays diverse roles in cancer initiation, progression, and drug resistance depending
on tumor type characteristics that are also associated with cancer stem cells (CSCs). Recurrence of breast
carcinomas may be attributed to the presence of breast CSCs (BCSCs). BCSCs exist in mesenchymal-like or
epithelial-like states and the transition between these states endows BCSCs with the capacity for tumor progression.
The discovery of a feedback loop with galectins during epithelial-to-mesenchymal transition (EMT) prompted us to
investigate its role in breast cancer stemness.
Method: To elucidate the role of Gal3 in BCSCs, we performed various in vitro and in vivo studies such as
sphere-formation assays, Western blotting, flow cytometric apoptosis assays, and limited dilution xenotransplant
models. Histological staining for Gal3 in tissue microarrays of breast cancer patients was performed to analyze the
relationship of clinical outcome and Gal3 expression.
Results: Here, we show in a cohort of 87 node-positive breast cancer patients treated with doxorubicin-based
chemotherapy that low Gal3 was associated with increased lymphovascular invasion and reduced overall survival.
Analysis of in vitro BCSC models demonstrated that Gal3 knockdown by small hairpin RNA (shRNA) interference in
epithelial-like mammary spheres leads to EMT, increased sphere-formation ability, drug-resistance, and heightened
aldefluor activity. Furthermore, Gal3negative BCSCs were associated with enhanced tumorigenicity in orthotopic
mouse models.
Conclusions: Thus, in at least some breast cancers, loss of Gal3 might be associated with EMT and cancer
stemness-associated traits, predicts poor response to chemotherapy, and poor prognosis.
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Background
Breast cancer is the leading cause of cancer-related
deaths in women [1]. Advances in the treatment of this
heterogeneous group of diseases are therefore a high pri-
ority. One approach is to detect and selectively target
cancer stem cells, a small subset of the tumor cell popu-
lation [2]. The cancer stem cell hypothesis suggests that
many cancers, including breast cancer, are driven by a
small subpopulation of cells that displays stem cell prop-
erties. These cells are rare, highly heterogeneous in na-
ture, and characterized by their tumorigenic potential
and unlimited self-renewal capability. They may mediate
tumor progression and, by virtue of their relative resist-
ance to chemotherapy and radiation, contribute to treat-
ment relapse [3, 4]. The definitive identification of
clinically relevant breast cancer stem cell (BCSC) sub-
groups that ultimately reduce patient survival, however,
remains a challenge. Recent studies have indicated a
close association between BCSCs and the acquisition of
an epithelial–mesenchymal transition (EMT) state [5].
BCSCs have been shown to exist in distinct
mesenchymal-like (EMT) and epithelial-like (mesenchy-
mal–epithelial transition; MET) states [6]. Mesenchymal-
like BCSCs have been characterized as CD24negative/
CD44positive and appear to be primarily quiescent and lo-
calized at the tumor invasive front. Epithelial-like BCSCs
in contrast tend to be proliferative and located more cen-
trally. The process of EMT plays an important role in em-
bryogenesis as well as in a number of biological processes
associated with cancer progression [7]. During EMT, epi-
thelial cells lose cell–cell contacts, undergo cytoskeletal
remodeling resulting in loss of polarity, and acquire a
mesenchymal morphology [8]. Interestingly, a number of
pathways that are known to regulate BCSC, including ca-
nonical and noncanonical Wnt signaling or transforming
growth factor beta (TGFβ) pathways, are also capable of
inducing EMT [9]. However, other pathways, such as the
human epidermal growth factor receptor (HER) signaling,
promote MET [10]. Although several BCSC markers have
been described, it is unclear whether these markers iden-
tify the same or distinct BCSCs.
Galectins are carbohydrate-binding proteins character-
ized by their binding affinity for β-galactosides and by
conserved sequences in the carbohydrate-binding site
[11]. It has been shown that galectin-3 (Gal3) is respon-
sible for a myriad of biological processes in a wide var-
iety of cancers. In breast cancers, Gal3 expression may
be associated with specific morphological precursor sub-
types and undergoes a transitional shift in expression
from luminal to peripheral cells as tumors progress to
comedo-type ductal carcinoma in situ or invasive carcin-
omas [12, 13]. Recently, a functional feedback loop be-
tween beta1 integrins and galectin-1 that involves the
epigenetic induction of galectin-1 expression during
integrin-induced EMT and cell scattering was identi-
fied [14].
The role of Gal3 CSCs is still controversial. Recently,
Chung and colleagues reported in a lung cancer model
that Gal3 correlated with tumor progression and in-
creased the CSC pool by activation of the Wnt signaling
pathway [15]. It was also suggested that Gal3 could be a
therapeutic target in some breast cancers [16].
Gal3 appears therefore to functionally and structurally
contribute to a number of BCSC hallmarks, which




The cell lines GI-101A and GI-LM2 were kind gifts from
Dr. Janet Price and described elsewhere [17]. GI-LM2G
are GI-LM2 cells with stable lentiviral knockdown of
Gal3 as described below. Cells were maintained and sub-
cultured as explained before [18].
Reagents
B27 supplement was purchased from Life Technologies,
Carlsbad, CA, USA (#17504-044), rhEGF from Sigma-
Aldrich, St. Louis, MO, USA (#E9644), and recombinant
human fibroblast growth factor (rhFGF) from BD Biosci-
ences, San Jose, CA, USA (#354060).
Sphere culture and sphere-formation assays
Parental cells were trypsinized, washed with phosphate-
buffered saline (PBS), and seeded in clonal density
(5–10 × 103/mL) in cancer stem cell (CSC) media
consisting of Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with L-glutamine, B27, recombin-
ant human epidermal growth factor (rhEGF) (10 ng/mL)/
rhFGF (10 ng/mL), and penicillin/streptomycin on ultra-
low attachment plates (Corning, Corning, NY, USA).
Conditioned media (CM) was changed every 3–4 days
and spheres trypsinized and reseeded for expansion in
higher generations. For quantification of sphere-
formation ability, single cell suspensions were seeded
into ultra-low attachment 96-well plates (500–1000
cells/100 μL) in CM plus 1 % methylcellulose. One
hundred microliters of the same media was added
after 3 days and exchanged after another 3–4 days.
Spheres were usually counted after 10 days. Only
spheres >75 μm in diameter were included, if not
otherwise stated.
shRNA silencing of galectin-3
Cells were infected with the galectin-3 shRNA (#sc-
155994-V) and nontargeting control shRNA (#sc-108080)
lentiviral particles (Santa Cruz Biotechnology, Dallas, TX,
USA) according to the manufacturer’s protocol. After
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transduction, stable cell lines expressing the galectin-3 (or
control) shRNA were isolated by selection with 2.5 pg/ul
puromycin (Santa Cruz Biotechnology; #sc-108071A).
Protein expression by Western blot analysis or cell surface
expression by flow cytometry was verified following
propagation for four passages.
Aldehyde dehydrogenase (ALDH) assay
Spheres were dissociated into single-cell suspension and
allowed to recover for 24 h in CSC media in low-
attachment plates. ALDH activity was monitored using
the ALDEFLUOR kit (Stemcell Technologies, Vancouver,
BC, Canada; #01700) following manufacturer’s instruc-
tions. The ALDH activity was analyzed by flow cytome-
try using the LSRFortessa and quantified by FlowJo 8.8.6
software, Multicycle cell software (FlowJo LLC., Ashland,
OR, USA).
Luciferase reporter assays
CSC cells were cultured in CSC medium in triplicate in
low-attachment 24-well plates. Lipofectamine 2000 (Life
Technologies; #11668-027) was used to transiently trans-
fect cells with either 500 ng inducible Firefly luciferase
expressing either SuperTOP or SuperFOP vector
(AddGene, Cambridge, MA, USA; plasmids #12456 and
#12457) for monitoring Wnt signaling or SBE4luc
(AddGene plasmid #16495) for monitoring TGFβ signal-
ing. Simultaneously, cells were cotransfected with consti-
tutively Renilla luciferase expressing normalization
control vector pRL-TK (Promega, Madison, WI, USA;
#E2241)) at a ratio of 50:1. Twenty-four hours after
transfection, Firefly and Renilla luciferase activity were
measured using Dual-Glo Luciferase Reporter Assay Sys-
tem (Promega; #E2920) and a microplate reader (Dynex
Technologies, Chantilly, VA, USA). The Renilla lucifer-
ase activity was normalized to the Firefly luciferase activ-
ity. All experiments were performed in triplicate.
Immunohistochemistry (IHC) and immunofluorescence (IF)
Immunohistochemical and immunofluorescence stain-
ings were carried out as described before [19]. Briefly,
paraformaldehyde (PFA)-fixed and paraffin-embedded
tissue sections underwent antigen retrieval in sodium
citrate buffer (pH 6.0) at boiling temperature for 20 mi-
nutes. Sections were washed in Tris-buffered saline
(TBS) plus 0.025 % Triton X-100 after cooling down,
blocked with 10 % goat serum, and incubated with pri-
mary antibody solutions at 4 ° C overnight. After several
washes, slides were directly incubated with secondary
antibody solution at room temperature for 1.5 hours in
the dark. Immunofluorescent slides were counterstained
with 4,6-diamidino-2-phenylindole (DAPI) and then
mounted in Fluorescence Mounting Medium (Dako,
Glostrup, Denmark). IHC sections were stained using
the VECTASTAIN Elite ABC Kit (Universal) according
to the manufacturer's instructions (Vector Laboratories,
Burlingame, MA, USA). For primary goat antibodies, we
used a horseradish peroxidase-conjugated anti-goat sec-
ondary antibody solution.
Cytoplasmic staining was scored by multiplying an in-
tensity score (0 = negative, 1 = weak, 2 = moderate, and
3 = strong) × the percentage of invasive tumor cells with
staining. A score of 150 or greater was considered high
expression.
In vivo xenograft experiments
Mouse experiments were performed in accordance with
the Institutional Animal Care and Use Committee
(IACUC) at M.D. Anderson. Immunocompromised age-
matched male 5- to 6-week-old, athymic, nu/nu, Balb/c
mice were purchased from an institutional breeder col-
ony and kept at 24 °C in sterile conditions with water
and food ad libitum. Different dilutions of GI-LM2 or
GI-LM2G cells were orthotopically implanted in 50 μL
PBS into the fourth mammary fat pad via a 27G needle.
Tumor growth was controlled and measured regularly
and mice were checked for their vital status and weight.
Tumor volume was calculated by the following formula:
mm3 = (width × width × length) / 2 [mm]. All mice were
sacrificed when their tumor volumes reached high
tumor burdens according to the IACUC protocol or at
the end of the experiment. Subsequently, tumor parts
that were selected for further in vitro cell culture experi-
ments were fixed in 4 % PFA for histological analyses.
Patients
This study was approved by The University of Texas
M.D. Anderson Cancer Center institutional review
board. Patients included in this retrospective study were
treated - after obtaining the necessary consent - on
Protocol DM86-12, a randomized study comparing six
cycles of 5-fluorouracil (5-FU), doxorubicin (A), and
cyclophosphamide (C) in the adjuvant setting to six cy-
cles of fluorouracil, doxorubicin, and cyclophosphamide
followed by four cycles of methotrexate and vinblastine.
Although patients ≥50 y of age with estrogen receptor-
positive disease were randomized to receive tamoxifen
or six cycles of fluorouracil, doxorubicin, and cyclophos-
phamide plus four cycles of methotrexate and vinblast-
ine, those who received tamoxifen were excluded from
our retrospective study, so all patients in our study re-
ceived doxorubicin-based chemotherapy without tam-
oxifen. The previous clinical protocol failed to show any
benefit from the addition of four cycles of methotrexate
and vinblastine to six cycles of fluorouracil, doxorubicin,
and cyclophosphamide, so both groups were regarded as
having similar doxorubicin-based chemotherapy.
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Inclusion criteria for this retrospective study were resect-
able stages II and IIIA breast cancer with axillary lymph
node metastases, surgical treatment with mastectomy and
axillary dissection without irradiation, age younger than 75
y at diagnosis, no evidence of distant disease at diagnosis,
and no history or concurrent malignancy. Additional entry
criteria included availability of sufficient archival paraffin-
embedded tumor tissue from the primary breast tumor to
obtain cores for tissue microarrays. All patients had surgery
done at M.D. Anderson Cancer Center between 1986 and
1994.
Tissue microarrays
To facilitate the efficient use of patient specimens, tissue
microarrays (TMA) were constructed. Paraffin blocks con-
taining tissue from the primary breast tumor were used.
The TMAs were prepared using a manual tissue puncher/
array (Beecher Instruments, Sun Prairie, WI, USA). Up to
six cores, 0.6 mm in diameter, were cut from each primary
tumor and aligned within the recipient block in a rectilinear
array. All cores were placed 0.2 mm apart in the recipient
blocks.
Statistical analyses
For the analyses of TMA results and patient outcome data,
locoregional recurrence-free (LRRF), disease-specific (DSS)
and overall survival (OS) estimates were calculated using
the Kaplan-Meier product limit method and were
expressed ± standard error. The two-sided log-rank test was
used to test the association between particular factors and
patient survival. All statistical analyses were carried out
using SSPS 12.0 for Windows (SPSS Inc., Chicago, IL,
USA). Locoregional recurrence-free survival was defined as
the interval from the date of surgery to the date of first
locoregional disease recurrence or to the last follow-up
date. All locoregional recurrences were scored as events re-
gardless of the presence of distant metastatic disease, and
patients without recurrence were censored at last follow-
up. Disease-specific survival was defined as the interval
from the date of surgery to the date of death due to breast
cancer. Overall survival was defined as the interval from
the date of surgery to the date of death from any cause.
Results are expressed as the mean ± standard error of
the mean (SEM). All statistical comparisons for the in
vitro and mouse data were made with a standard t test,
using biostatistics software from GraphPad Prism® (La
Jolla, CA, USA). The criteria for significance were p < 0.05
(*), p < 0.01 (**), and p < 0.001 (***) for all comparisons.
Additional methods can be found in the Additional file 1.
Results
Gal3 expression, clinicopathological features, and survival
To assess the clinical relevance of Gal3 expression and
BCSC features, we investigated a cohort of 87 node-
positive breast cancer patients treated with doxorubicin-
based chemotherapy (FAC; 5-fluorouracil, adriamycin,
cyclophosphamide).) with respect to tumor recurrence
and survival. Tissue microarrays (TMAs) were prepared
from the primary tumors and stained for Gal3 (Fig. 1a).
The clinicopathological variables of the patients in this
cohort are illustrated in Table 1. No association of Gal3
expression with any particular morphology or distribu-
tion pattern was evident in these tissue microarray spec-
imens. The subcellular distribution of Gal3 was generally
cytoplasmic. Only three of the tumors had nuclear
expression, which was too few for meaningful ana-
lysis. Cytoplasmic staining was evaluated by H-score
classification, where a score of 150 or greater was
considered high expression. We could not detect any
statistically significant difference in Gal3 expression with
respect to age (p = 0.41), race (p = 0.25), menopausal status
(p = 0.57), number of lymph node metastasis (p = 0.36), or
hormone receptor status (ER p = 0.56; PR p = 0.37; HER2
p = 0.21). However, we found that the lymphovascular in-
vasion significantly correlated with low Gal3 expression
(p = 0.01) (Table 1).
Subsequent univariate analysis revealed that low
Gal3 expression is associated with decreased locore-
gional recurrence-free, disease-specific and overall sur-
vival (p = 0.034, p = 0.18, and p = 0.019, respectively)
(Table 2 and Fig. 1b). Multivariate analysis demonstrated
statistically significant correlations with ≥10 positive
lymph nodes (p = 0.020) in locoregional recurrence-free
survival, low Gal3 in disease-specific survival (p = 0.003)
and overall survival (p = 0.014), respectively, and HER2
IHC score in locoregional recurrence-free or overall
survival (p = 0.003 and p = 0.001, respectively) (Table 2).
Analysis of data from The Cancer Genome Atlas (TCGA)
demonstrated that gene expression (LGALS3) de-
creases sequentially from normal tissue to ductal
breast carcinoma in situ to invasive ductal breast car-
cinoma (Additional file 2: Figure S1A). Moreover, it
appears that LGALS3 expression is lower at metastatic
sites compared to primary breast tumors (Additional
file 2: Figure S1B). Although not statistically signifi-
cant, we were also able to detect more cases with low
Gal3 expression in higher tumor stages (p = 0.22) and
tumor grades (p = 0.41) in our patient cohort (Table 1).
Together, these data suggest that lower Gal3 expres-
sion is associated with advanced locoregional invasion
and poor survival.
Gal3 expression in isogenic epithelial breast cancer cells
To further investigate the mechanisms which explain
our findings, we examined isogenic cell lines which dif-
fer in their metastatic potential. GI-101A is an estrogen-
receptor and EGFR-positive, basal-like low metastatic
cell line derived from a primary infiltrating ductile breast
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tumor [20] and its counterpart GI-LM2 is a highly meta-
static variant that was isolated from repeated lung me-
tastasis of GI-101A (Additional file 2: Figure S1C) [17].
Western blot analysis revealed that total Gal3 expression
was higher in GI-01A than in GI-LM2 cells (Fig. 2a).
Complete depletion of Gal3 by shRNA (delivered by len-
tiviral particles) in GI-LM2 cells (designated GI-LM2G)
was verified by Western blot of whole cell lysates
(Fig. 2a). Low surface Gal3 expression was also main-
tained after culture in anoikis-resistant sphere condi-
tions (Fig. 2b). Gal3 depletion was associated with a
striking transition in the morphology of GI-LM2G cells
in adherent (Fig. 2c, left panel) as well as sphere condi-
tions (Fig. 2c, right panel). The grape-like phenotype
encountered in GI-LM2G spheres corresponds to mes-
enchymal features in pancreatic cancer cells [19], which
prompted us to analyze further EMT markers. GI-
LM2G, but not its control cell line GI-LM2C (infected
with lentiviral particles harboring a nontargeting
shRNA), acquired a mesenchymal-like morphology with
spindle-like phenotype whereas GI-101A, GI-LM2 or
GI-LM2C formed epithelial-like cell clusters. Moreover,
EMT after galectin-3 depletion was further supported by
the diminished expression of epithelial markers, E-
cadherin and cytokeratin 18 (CK18) and the reappear-
ance of the mesenchymal marker vimentin in GI-LM2G
by Western blot analysis (Fig. 2d). EMT features after
Gal3 depletion remained stable as evidenced by im-
munofluorescence staining for the same markers in
spheres (Additional file 2: Figure S2A and S2B). Because
EMT has been closely connected with cancer stemness in
breast cancer, we examined the expression of commonly
accepted BCSC surface markers by flow cytometry [5].
Loss of Gal3 was associated with a slightly increased
population of CD24negative/CD44positive cells (58.1 % in
GI-101A vs 64.7 % in GI-LM2G, N.S.) (Fig. 2e, upper
panel). When analyzed in greater detail, we found that
Gal3low-expressing breast cancer cells from all cell lines
consistently contained a larger population of BCSC
marker-positive subgroups compared to their Gal3high
counterparts, (in GI-101A 52.2 % vs. 38.8 %, in GI-
LM2C 43.3 % vs. 25.4 % and GI-LM2G 66.2 % vs.
39.7 %) (Additional file 2: Figure S3A). Loss of Gal3 also
led to a decreased expression of EpCAM, an epithelial
cell adhesion protein, further suggesting a loss of epithelial
cell characteristics (Fig. 2e, lower panel and Additional file
2: Figure S3B).
These findings suggest that changes in Gal3 expression
lead to alterations of the EMT state in breast cancer cells
which remains a conserved hallmark in mammary spheres.
Loss of Gal3 increases functional CSC characteristics in
breast cancer spheres
We next investigated whether loss of Gal3 affects BCSC
properties including self-renewal capability, Aldefluor ac-
tivity, and drug resistance. Sphere-formation assays dem-
onstrated that the cell line with higher metastatic potential
(GI-LM2C) formed more than twice as many spheres as
low-metastatic GI-101A cells. GI-LM2G cells displayed an
even higher sphere-forming capacity compared to GI-
LM2C (Fig. 3a and Additional file 2: Figure S4A). This in-
versely correlated with the Gal3 expression of these cell
lines. In line with that, Gal3 depletion in GI-101A led to a
significantly enhanced sphere-formation ability (Additional
file 2: Figure S4B). Aldefluor activity has been reported to
correlate very well with CSC potential in different tumor
types [21, 22]. The cell line GI-101A had the lowest
(26.6 %), GI-LM2C intermediate (39.7 %) and GI-LM2G
the highest Aldefluor activity (72.8 %) (Fig. 3b). FAC (5-
fluorouracil (5FU), doxorubicin (adriamycin), and cyclo-
phosphamide) is a widely used chemotherapy regimen
used for treatment of early and node-positive breast cancer
Fig. 1 Low galectin-3 (Gal3) expression correlates with poor outcome in node-positive breast cancer. a Representative pictures of IHC staining
for Gal3 in TMAs with examples for Gal3 high (upper panel) and Gal3 low (lower panel). b Tumor microarrays (TMA) of node-positive breast cancer
patients were stained for Gal3. High Gal3 expression shows better locoregional relapse-free (LRRF) survival (left panel), better disease-specific
survival (DSS) (middle panel) as well as better overall survival (OS) (right panel) than low Gal3 expression in node-positive breast cancer
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and was part of the regimen in our patient cohort as well
[23]. Exposure of BCSCs to clinically relevant doses of
FAC resulted in 83.0 % cell death in GI-LM2C spheres
while almost all GI-LM2G spheres were completely resist-
ant (only 7.68 % cell death was observed) (Fig. 3c).
Further, when investigating cell cycle (Fig. 3d) and cell
growth of spheres by MTT proliferation assays (Fig. 3e),
we found that GI-LM2C spheres displayed significantly
higher numbers of cells in G2 phase (23.4 ± 9.04 % vs.
8.97 ± 1.58 %) and grew faster when compared to GI-
LM2G spheres. This is in line with observations of Liu et
al. that mesenchymal cells are rather quiescent whereas
epithelial BCSCs seem to be more proliferative [6].
Collectively, these functional assays demonstrate that
Gal3negative breast cancer cells are not only characterized
by morphological differences, but also display functional
in vitro differences that strongly suggest an association
between the absence of Gal3 and BCSC characteristics.
Canonical Wnt signaling activity and AKT activity are
associated with Gal3 expression in epithelial CSC-like spheres
In an attempt to determine their underlying mechanisms
with respect to breast cancer stem cell signaling, we ana-
lyzed three reported pathways commonly involved in
BCSC regulation. Canonical Wnt and TGFβ signaling
have recently been linked to lung metastasis in breast
Table 1 Gal3 expression according to clinicopathologic
variables
Variable Total patients High Gal3 Low Gal3
Age p = 0.41
20–35 yr 7 2 5
36–50 yr 48 12 36
51–70 yr 31 9 22
> 70 yr 1 0 1
Race p = 0.25
Black 7 3 4
White 61 18 43
Hispanic 14 2 12
Other 5 0 5
Menopausal status p = 0.57
Pre 47 13 34
Post 37 10 27
Unknown 3 0 3
pT stage p = 0.22
pT1 (0–2 cm) 22 9 13
pT2 (2–5 cm) 55 13 42
pT3 (>5 cm) 7 1 6
Unknown 3 0 3
Tumor grade p = 0.41
1 5 2 3
2 38 12 26
3 44 9 35
pN stage p = 0.36
N1 (1–3 LN) 60 16 44
N2 (4–9 LN) 19 5 14
N3 (>9 LN) 8 2 6
Lymphovascular invasion p = 0.01
Present 38 5 33
Absent 49 18 31
ER p = 0.56
Positive 53 13 40
Negative 33 10 23
Unknown 1 0 1
PR p = 0.37
Positive 40 9 31
Negative 45 14 31
Unknown 2 0 2
HER2 p = 0.21
0 48 13 35
1+ 13 2 11
Table 1 Gal3 expression according to clinicopathologic
variables (Continued)
2+ 5 0 5
3+ 20 8 12
Unknown 1 0 1
Gal3 galectin-3, ER estrogen receptor, HER2 human epidermal growth factor
receptor 2, PR progesterone receptor
Table 2 Variables associated with clinical outcome




p = 0.017 ≥10 positive
lymph nodes
p = 0.020
Low Gal3 p = 0.034
Disease-specific survival (DSS)
Univariate Multivariate
Low Gal3 p = 0.018 Low Gal3 p = 0.003
p = 0.003
Her2 IHC score p = 0.008 HER2 IHC score
Race p = 0.030
Overall survival (OS)
Univariate Multivariate
Low Gal3 p = 0.019 Low Gal3 p = 0.014
Her2 IHC score p = 0.015 HER2 IHC score p = 0.001
Gal3 galectin-3, HER2 human epidermal growth factor receptor 2,
IHC immunohistochemistry
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cancer cells [24]. We therefore carried out SuperTOP/
FOP Luciferase assays (STP) in GI-LM2C and GI-LM2G
spheres to analyze the baseline activity of canonical Wnt
signaling. Surprisingly, we found that STF activity was
higher in Gal3positive GI-LM2C spheres and significantly
lower in GI-LM2G spheres (Fig. 4a). These findings are in
accordance with previous reports of a positive correlation
between Gal3 expression and canonical Wnt signaling
[25]. In line with these findings we observed that surface
expression of the Wnt target gene, LGR5, was lower in
Gal3negative GI-LM2G (green line) than in GI-LM2C
spheres (red line) (Fig. 4b) and the protein expression of
typical Wnt targets Axin2 and Tcf4 was robustly reduced
in GI-LM2G spheres (Additional file 2: Figure S4C).
When examining TGFβ signaling activity, we found no
statistically significant difference between GI-LM2C and
GI-LM2G as examined by SBE4luc luciferase readouts
(Fig. 4c). Strikingly, however, GI-LM2C demonstrated
high phospho-AKT activity (p-AKT) indicating activation
of the AKT pathway, whereas GI-LM2G did not show any
p-AKT on Western blot analysis (Fig. 4d). The latter re-
sults are consistent with previous findings showing that
Gal3 can activate AKT in bladder cancer cells [26]. AKT
pathway activation has also been associated with increased
proliferation [27]. Together, we found that activation of
AKT and Wnt in Gal3positive epithelial spheres was accom-
panied by increased cell cycle and heightened proliferation
as shown in Fig. 3d and e. These observations support the
concept that epithelial-like spheres are proliferative and
mesenchymal-like BCSCs are quiescent [6].
Breast CSCs with low Gal3 expression possess heightened
tumorigenicity in vivo
The consensus gold standard for cancer stemness is
tumor growth in vivo following injection of serially di-
luted cells. Thus, we injected 2.5 × 105, 1 × 105, 1 × 104,
Fig. 2 Galectin-3 (gal3) expression is intertwined with an epithelial phenotype. a Western blot on Gal3 in the breast cancer cell lines GI-101A,
GI-LM2, GI-LM2G, and GI-LM2C. b Surface Gal3 expression of spheres was detected by flow cytometry. IgG control is shown in black, Gal3 expression
of GI-101A (grey, left panel), Gal3 expression of GI-LM2C (red, middle panel), and Gal3 expression of GI-LM2G (green, right panel). c Bright field pictures
of adherent cells and mammosphere cultures of breast cancer cells used in (a). d Western blot on EMT markers (E-cadherin, cytokeratin-18 (CK18),
vimentin) in breast cancer cells used in (a). The same blot is used as in (a). e Flow cytometry on the cancer stem cell markers CD24, CD44,
EpCAM, and Gal3 of parental breast cancer cells. The upper panel shows the typically analyzed CD24neg/CD44pos CSCs and the lower panel
displays EpCAMneg/Gal3neg populations out of the CD24neg/CD44pos CSC pool
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1 × 103, and 1 × 102 GI-LM2C (red) into the right and
GI-LM2G sphere-derived single cells (green) orthotopi-
cally into the left fourth mammary gland/fat pad of fe-
male, athymic nu/nu mice (Fig. 5a, right panel). Tumors
of GI-LM2G cells grew significantly faster (Fig. 5a, left
panel) and also at all dilutions (Fig. 5b), whereas GI-
LM2C tumors grew slower, formed smaller tumors, and
did not grow at the lowest dilution (Fig. 5b, right panel).
Hematoxylin and eosin stain of the tumors revealed typ-
ical examples of invasive ductal carcinoma with architec-
tural patterns, such as large sheets of tumor cells as well
as cords or nests of varying size (Fig. 5c, left pictures).
Immunohistochemistry (IHC, middle pictures) and im-
munofluorescence staining for Gal3 (right pictures) in sec-
tions of the tumor xenografts confirmed Gal3 expression
in GI-LM2C-derived tumors, whereas GI-LM2G-derived
tumors remained negative for Gal3 (Fig. 5c).
Discussion
Here, we present evidence that Gal3 expression is linked
to an epithelial phenotype (EpCAM+ and E-cadherin+),
lower drug resistance, and decreased tumorigenicity in hu-
man breast cancer cells. In contrast, Gal3negative BCSCs
are highly tumorigenic, phenotypically mesenchymal,
drug-resistant, and enriched in BCSC marker (CD24-/
CD44+)-expressing cells compared to Gal3positive cells as
summarized in Fig. 6. These results are surprising, be-
cause Gal3 expression has been previously associated with
characteristics associated with CSCs, including tumor pro-
gression, in other cancer types [15, 18, 28–31].
Fig. 3 Loss of galectin-3 (Gal3) leads to an increase of functional CSC abilities. a Breast cancer cells were seeded into sphere-formation assays
(SFA). Loss of Gal3 correlates with the inherent SFA ability displayed as number of spheres per 1000 seeded cells (n = 3). b Aldefluor activity of
the breast cancer cell lines GI-101A, GI-LM2, and GI-LM2G was determined by flow cytometry. Similar to (a), loss of Gal3 increased the percentage
of Aldefluorpos cells from 26.6 % (GI-101A) and 39.7 % (GI-LM2) to 72.8 % (GI-LM2G). c Drug resistance to the FAC regimen (5-fluorouracil (5-FU),
doxorubicin (adriamycin), and cyclophosphamide) was evaluated in CD24neg/CD44pos CSCs of GI-LM2C and GI-LM2G by APO-BrDU TUNEL assay
(detected by an Alexa Fluor™ 488 dye-labeled anti-BrdU antibody as shown on the y-axis). GI-LM2C undergo cell death upon treatment, whereas
GI-LM2G are mostly resistant (83.0 % vs. 7.68 %). d Cell cycle distribution was carried out by propidium iodide staining of GI-LM2 (red, left panel)
and GI-LM2G (green, right panel) and evaluated by flow cytometry. Numbers including standard deviations are shown in the table. e MTT proliferation
assay of spheres of GI-LM2 (red) and GI-LM2G (green) over 3 days. The relative OD490 on day 1 was defined as the starting point. Experiments were
repeated at least three times. The criteria for significance were p < 0.05 (*) and p < 0.01 (**)
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The in vitro and in vivo data presented in this study
are in line with TMA analysis of node-positive breast
cancer patients, which revealed that patients with Gal3-
negative tumors had significantly worse outcomes with re-
spect to locoregional relapse-free (LRRF) survival,
disease-specific survival (DSS) and overall survival (OS).
Moreover, we were able to detect trends that tumors
with advanced T and N stages or higher tumor grading
seemed to express less Gal3. Lymphovascular invasion
was significantly associated with lower Gal3 expression.
These results are strengthened by analysis of data from
The Cancer Genome Atlas, which also revealed lower
Gal3 expression in advanced stage breast cancers.
All of these hallmarks of tumor progression have been
reported to be associated with a higher BCSC pool. The
BCSC pool can be expanded by epithelial–mesenchymal
transition [32, 33]. Here, we were able to demonstrate in
our in vitro model system that depletion of Gal3 leads to
EMT with subsequent reinforcement of CSC-like features.
Despite the association of Gal3 expression in BCSCs
with reduced drug resistance and low tumorigenicity in
our model system, canonical Wnt signaling and AKT ac-
tivity were found to be higher in Gal3positive BCSCs. This
is in line with previously published findings [25] and
suggests a role for Gal3 as regulator of essential cancer
pathways. Activity of both pathways has been linked to
increased proliferation, which was evident in the epithe-
lial Wnt- and AKT-positive BCSCs (Fig. 6). The role of
Gal3 in individual processes which affect progression in
breast cancer and their dynamic interactions therefore
need to be further determined.
Breast cancer is not a singular, homogeneous disease,
but rather a very heterogeneous malady with a variety of
subtypes (basal, claudin-low, HER2+, luminal A/B,
triple-negative) [34]. The patient cohort we examined
represents a selected and small subset of estrogen
receptor-positive and node-positive breast cancer pa-
tients who received doxorubicin-based chemotherapy,
but never tamoxifen, during the course of treatment.
Therefore, we cannot draw general conclusions about
the role of Gal3 in all breast cancer subtypes or in node-
negative, untreated patients.
It remains to be determined whether the biological
and clinical behavior of other breast cancer subtypes can
be characterized by Gal3 expression, and whether Gal3
might be an inducer of a subtype switch [35]. Gal3
Fig. 4 Knockdown of galectin-3 (Gal3) reduces canonical Wnt and AKT signaling in CSC-like spheres. a Canonical Wnt signaling activity was
evaluated by SuperTOP/FOP (STF) assays and normalized to Renilla luciferase (RLU = relative light units). Baseline Wnt activity was reduced in
Gal3negative GI-LM2G spheres (grey column) compared to Gal3positive GI-LM2C spheres (white column). b Flow cytometric analysis of the Wnt
target gene LGR5 in GI-LM2C (red) and GI-LM2G (green) spheres. Canonical Wnt activity in (a) correlated with LGR5 expression. c TGFβ signaling
was evaluated by SBE4-luc assays measured as normalized firefly to Renilla luciferase activity (RLU = relative light units). GI-LM2C (red column)
and GI-LM2G (green column) revealed no significant difference in TGFβ activity. d Western blot analysis shows typical results for EMT markers
(E-cadherin, vimentin), Gal3 as well as phospho-AKT/total-AKT in GI-LM2C and GI-LM2G spheres. P-AKT was absent in GI-LM2G. Experiments
were carried out in triplicate (n = 3)
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might also be differentially expressed during the various
processes involved in tumorigenesis and metastasis. It is
conceivable, for instance, that Gal3 does not play a sig-
nificant role in primary tumor growth, but becomes im-
portant in progression of sessile epithelial to circulating
and mesenchymal tumor cells [36], protective against
anoikis-induced cell death [26], and the process of endo-
thelial attachment and subsequent extravasation.
It will be important to evaluate the expression of Gal3
in circulating tumor cells, and its role as a predictive
biomarker in determining response to therapy and DSS
and OS in prospective clinical trials in a variety of breast
cancer patients.
Conclusions
In summary, we present compelling evidence that in a
select subgroup of breast cancers, loss of Gal3 is associ-
ated with a mesenchymal BCSC subtype and enhanced
Fig. 5 Low galectin-3 (Gal3) correlates with heightened tumorigenicity. a GI-LM2C (red) and GI-LM2G (green) sphere cells were injected into the
fourth mammary fat pad of mice with rapid tumor growth in GI-LM2G (upper panel) (n≥ 3). A representative picture of mice used in this study is
shown (red arrow = injection site for GI-LM2C; green arrow = injection site for GI-LM2G). b In vivo tumorigenicity assay with limited dilution; shown
are the tumor-free survival curves for 10,000 (left), 1000 (middle), and 100 (right) injected cells (GI-LM2C (red) and GI-LM2G (green)). c Sections of
the tumor specimens from experiments in (a) and (b) were stained for hematoxylin and eosin (H&E), Gal3 (IHC), and Gal3 IF (to the left, GI-LM2C,
to the right GI-LM2G)
Fig. 6 Graphical illustration of the proposed model. Model that
shows the characteristics of galectin-3 (Gal3)positive epithelial BCSCs
(green, left) and Gal3negative mesenchymal BCSCs (red, right)
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tumorigenicity, predicts poor response to chemotherapy,
and therefore correlates with poor prognosis.
Additional files
Additional file 1: Supplementary experimental procedures. (DOCX 16 kb)
Additional file 2: Figure S1. The Cancer Genome Atlas (TCGA) data
show the gene expression of Gal3 (LGALS3) in normal (no value), ductal
breast carcinoma in situ and invasive ductal breast carcinoma (A) or
normal (no value), primary site and metastatic site of human breast
cancer samples (B). (C) Western blot analysis of whole cell lysates of GI-
101A and its derivatives (GI-LM2, GI-LM2C, GI-LM2G) on estrogen receptor
(ER) expression. Figure S2 (A) Immunofluorescence staining of GI-LM2C
(upper row) and GI-LM2G spheres (lower row) for Gal3 (red), E-cadherin
(CDH1, green), and vimentin (gray). (B) Immunofluorescence staining of the
same cell lines for cytokeratin 18 (red) and vimentin (green). Counterstaining
with DAPI (blue) was used to visualize cell nuclei. Figure S3 (A) Flow
cytometric analysis shows that Gal3-positive populations (in red) of the
same cell line consistently contain a lower BCSC pool than Gal3-negative
populations (in green). (B) Correlation of Gal3 with CD24 and EpCAM
expression is listed in a table. Figure S4 (A) Brightfield pictures of spheres in
low magnification. Figure is related with Fig. 3a. (B) Sphere-formation assay
and its quantification of GI-101A, GI-101A after knockout of Gal3 (GI-101A-G)
as well as derivatives GI-LM2C and GI-LM2G. (C) Western blot of whole cell
lysates of GI-LM2C and GI-LM2G for Wnt targets Axin2 and Tcf4. Loading
control β-actin was used. The same membrane is used in Fig. S1C.
(PPTX 2636 kb)
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